Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.
EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.
Stemnovate is a unique, innovative drug development platforms enable the right patients to be targeted with the right treatments, at the right time.
Awakn Life Sciences is a biotechnology company with clinical operations that develops and delivers psychedelic medicine to better treat addiction. Awakn's team consists of chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction.
Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.
Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.
Biotangents was founded upon their Leapfrog Assembly™ platform technology for building complex genetic constructs from multiple DNA parts. This was developed through a SMART: Scotland award from Scottish Enterprise and was exe0mplified through the generation of their terpenoid biosynthesis strains. During that successful first year they also developed their DNA randomisation technology, Short Sequence Randomisation™. In 2016, having formulated a concept for a modular cell-free nucleic acid detection technology, Moduleic Sensing™, and with support from SynbiCITE, they commenced development of their first diagnostic test, a highly specific and sensitive solution for pen-side diagnosis of infectious diseases in livestock.
PheroSyn develops and produces novel pest pheromones. PheroSyn is a spin-out from Rothamsted Research, the world-leading, non-profit research centre that focuses on strategic agricultural science to the benefit of farmers and society worldwide.
PheroSyn develops and produces novel pest pheromones. PheroSyn is a spin-out from Rothamsted Research, the world-leading, non-profit research centre that focuses on strategic agricultural science to the benefit of farmers and society worldwide.
CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in the development of Organ-on-Chip technology aimed at enhancing preclinical drug testing for pharmaceutical and biotech companies. Established in 2008, the company offers microphysiological systems and consumables that enable the analysis of novel compounds for toxicity and safety in various biological models. Its flagship product, the LiverChip®, supports a full viral lifecycle model of hepatitis B, known as Quantum-B®, which is utilized in drug discovery collaborations with leading firms. By closely collaborating with academic experts in bioengineering and receiving support from notable organizations, CN Bio is committed to advancing the next generation of organ-on-chip platforms to facilitate faster development of therapies for serious diseases, ultimately improving health outcomes globally.
Light Science Technologies is passionate about delivering lighting, science, and research-proven plant monitoring solutions that help growers grow more with less.
Near-Life specializes in immersive learning content, focusing on the integration of interactive video and gaming technology for training purposes. The company has developed an online learning platform that employs a gaming approach to enhance eLearning experiences. By combining video scenarios with role-play elements, Near-Life provides users with an engaging and intuitive training method. This innovative approach allows learners to actively participate in their education, making the training process more effective and enjoyable. As pioneers in the field, Near-Life continues to advance the intersection of technology, learning, and media.
Sense Biodetection Limited is a molecular diagnostics company focused on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology.
Bionema is a leading biopesticide product testing and technology development company, specialising in chemical-free, organic crop protection. Research is focused on the development of natural products to protect crops from insect damage, reducing the use of synthetic pesticides, enhancing food security and increasing crop yields. Bionema supplies specialist bio-control products to the horticulture, turf and amenity and forestry sectors, providing training aimed at increasing the product efficacy.
Orbit Discovery is a peptide display company identifying potential peptide drugs for a range of chronic diseases. Peptides offer the potential to make drugs with the specificity and efficacy of large biologic molecules combined with the smaller dose size, simpler routes of delivery and lower cost of manufacturing found with small molecules. They are, therefore, uniquely suited to the treatment of chronic diseases which impact large patient populations. Their technology supports all of the improvements that can be made to peptides which make them better drugs whilst simplifying the discovery process and accelerating drug development
Roslin Cells is the parent company of Roslin Cell Therapies. Based in Edinburgh, UK Roslin Cell Therapies has a wealth of expertise, capabilities and industry recognition in process translation to GMP, development, optimization, scale up and the GMP manufacture of Cell Therapy and Advanced Therapy Medicinal Products (ATMPs).
Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.
Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, focused on developing innovative antibiotics to combat antibacterial resistance. Utilizing its SASPject platform, the company delivers anti-bacterial proteins, including small acid-soluble spore proteins, to specific bacterial species through targeted non-delivery vehicles. Phico's product pipeline includes SASPject PT3, an antibiotic aimed at Pseudomonas aeruginosa; SASPject PT4 and PT5, designed for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2, which targets Staphylococcus aureus. Additionally, the company is developing an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses along with antibacterial proteins to inhibit bacterial reproduction and toxin release. Founded in 2000, Phico Therapeutics is committed to advancing solutions for pressing healthcare challenges posed by antibiotic resistance.
Sentinel Oncology was founded in 2005 in Cambridge, UK and is a drug discovery company dedicated to the development and commercialisation of new therapeutics to treat cancer patients for whom there is currently an unmet medical need. The Sentinel Oncology portfolio includes two programmes progressing towards IND. We are further developing a novel approach, “Targeted Synergy” that is designed to enhance therapeutic index by delivering the effects of drugs directly to the tumour. Sentinel oncology is a fully integrated drug discovery company seeking to develop high quality drug candidates for partnering with the biotechnology and pharmaceutical industry. Our strategy relies on seeking partners and collaborators to maximise the value of our programmes.
Cobra Biologics is a leading international contract manufacturing organisation (CMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market. As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries. Cobra is a Contract Manufacturing Organisation (CMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viruses, phage and cell line derived products and pharmaceuticals for clinical trials and commercial supply. Over 15 years of track record in producing biologics and pharmaceuticals for use in pre-clinical to Phase III clinical trials and commercial supply has given our people a unique knowledge base as both manufacturer and also as service providers for the global life sciences market. We offer a broad range of integrated and stand-alone development services, stretching from cell line development to the supply of investigational medicinal product for clinical trials and commercial market supply.
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture. Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient’s cells. This can be either in vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body. Their pipeline of seven gene and cell therapy therapy products addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular and central nervous system disorders. Their product candidates have the potential to transform treatment landscapes. Their strategy is to develop their product candidates to their next value inflection points whilst continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.
BioSystems Technology focuses on developing alternative research models to meet scientific needs while reducing regulatory burdens and ethical concerns related to mammalian use. Founded by an infectious disease research fellow and a professor of molecular pathogenicity at the University of Exeter, the company specializes in creating models for microbiological research on fungal and bacterial pathogens. These innovative research models facilitate drug discovery and toxicity testing, allowing scientists to achieve rapid and reproducible results in their studies.
Touchlight Genetics develops a DNA production platform designed for the development of DNA vaccines for oncology and infectious diseases. Founded in 2007, Touchlight brings together a highly talented scientific and drug development team supported by an experienced board. Founder and CEO Jonny Ohlson has assembled a dynamic management team, including Clive Dix, Non-Executive Chairman, and John Tite, Executive Head of Research (formerly founding CEO of Bicycle Therapeutics), with substantial experience in growing life science companies and particularly in DNA vaccines. Touchlight is supported by a group of Non-Executive Directors, who bring a wealth of healthcare and entrepreneurial experience. Led by experienced drug pharmaceutical scientists Neil Porter and Jill Makin, Touchlight’s scientific team- some of the brightest talents in the UK industry- has successfully established and patented the proTLx™ synthetic DNA platform as well as successfully establishing the first therapeutic proof-of-principle through collaboration with leading academic partners. The company has established strong collaborative links with academic laboratories worldwide including Imperial College London, Southampton University, Queen’s University Belfast and the University of Pennsylvania in the US.
CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in the development of Organ-on-Chip technology aimed at enhancing preclinical drug testing for pharmaceutical and biotech companies. Established in 2008, the company offers microphysiological systems and consumables that enable the analysis of novel compounds for toxicity and safety in various biological models. Its flagship product, the LiverChip®, supports a full viral lifecycle model of hepatitis B, known as Quantum-B®, which is utilized in drug discovery collaborations with leading firms. By closely collaborating with academic experts in bioengineering and receiving support from notable organizations, CN Bio is committed to advancing the next generation of organ-on-chip platforms to facilitate faster development of therapies for serious diseases, ultimately improving health outcomes globally.
Sentinel Oncology was founded in 2005 in Cambridge, UK and is a drug discovery company dedicated to the development and commercialisation of new therapeutics to treat cancer patients for whom there is currently an unmet medical need. The Sentinel Oncology portfolio includes two programmes progressing towards IND. We are further developing a novel approach, “Targeted Synergy” that is designed to enhance therapeutic index by delivering the effects of drugs directly to the tumour. Sentinel oncology is a fully integrated drug discovery company seeking to develop high quality drug candidates for partnering with the biotechnology and pharmaceutical industry. Our strategy relies on seeking partners and collaborators to maximise the value of our programmes.
Sphere Fluidics Limited is a new Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.
Plasticell is a privately held biotechnology company using novel cell culture and drug discovery platforms to produce regenerative small molecule drugs. Plasticell aims to develop drugs by elucidating the biochemical mechanisms that control the proliferation and differentiation of stem cells, the master cells responsible for tissue development and repair.
Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.
Stemnovate is a unique, innovative drug development platforms enable the right patients to be targeted with the right treatments, at the right time.
LIFNano Therapeutics, established in 2013 as a spin-out from the University of Cambridge, is a clinical-stage company dedicated to the development of targeted therapies for neurodegenerative diseases, particularly multiple sclerosis. The company specializes in utilizing nanotechnology to deliver the biologic Leukaemia Inhibitory Factor (LIF), aiming to repair damaged tissues, including neurons in the brain and spinal cord. By focusing on natural treatment options, LIFNano Therapeutics seeks to provide innovative solutions for patients suffering from multiple sclerosis and other inflammatory diseases affecting the brain and immune system.
Oxford Genetics is a UK-based biotechnology company specializing in the production of versatile cloning plasmids for research in academic and biotechnology institutions. They also provide custom cloning and DNA synthesis. All of their products are free of intellectual property restrictions.
Isansys Lifecare is a digital healthcare company that has developed a patient status engine and a user-friendly, sophisticated patient monitoring platform. The PSE automates fundamental healthcare procedures. They focused on developing new patient-centered technology and data-driven methods in hospitals and healthcare organizations throughout the world.
Sentinel Oncology was founded in 2005 in Cambridge, UK and is a drug discovery company dedicated to the development and commercialisation of new therapeutics to treat cancer patients for whom there is currently an unmet medical need. The Sentinel Oncology portfolio includes two programmes progressing towards IND. We are further developing a novel approach, “Targeted Synergy” that is designed to enhance therapeutic index by delivering the effects of drugs directly to the tumour. Sentinel oncology is a fully integrated drug discovery company seeking to develop high quality drug candidates for partnering with the biotechnology and pharmaceutical industry. Our strategy relies on seeking partners and collaborators to maximise the value of our programmes.
Locate Bio is a world leading orthobiologics company focused on providing surgeons with best-in-class products. Its clinical-stage product, LDGraft, is a controlled and extended-release rhBMP-2 for the treatment of chronic low back pain. CognitOss is in the discovery phase for the treatment of antimicrobial-resistant (AMR) infections.
Prokarium is a biopharmaceutical company leading the oncology field of microbial immunotherapy The Company’s pipeline is designed to unlock a new generation of immuno-oncology therapeutics by re engineering evolution into a synthetic biology platform Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune driven, long lasting antitumor effects
Isogenica Limited is a biotechnology company based in Little Chesterford, United Kingdom, that specializes in designing and licensing synthetic antibody libraries and display technologies for antibody discovery. The company offers several systems, including the llamdA System for single-domain antibodies, the Xab System for human antibody fragments, and the 4D Fab System for synthetic human antibodies. Additionally, Isogenica provides peptide and scaffold platforms to facilitate the development of therapeutic peptides aimed at treating diseases. Its proprietary vitro display technology, known as CIS display, is employed to discover biologically active peptides, proteins, and antibodies. The company's innovative small-format antibodies can be utilized to create bispecific and multi-specific biotherapeutics, enhancing targeted drug delivery in applications such as antibody-drug conjugates and cell and gene therapies. Established in 1998 and originally named Pharmacophorix Limited, Isogenica serves pharmaceutical and biotechnology sectors, contributing significantly to advancements in medical research and therapeutic development.
Sentinel Oncology was founded in 2005 in Cambridge, UK and is a drug discovery company dedicated to the development and commercialisation of new therapeutics to treat cancer patients for whom there is currently an unmet medical need. The Sentinel Oncology portfolio includes two programmes progressing towards IND. We are further developing a novel approach, “Targeted Synergy” that is designed to enhance therapeutic index by delivering the effects of drugs directly to the tumour. Sentinel oncology is a fully integrated drug discovery company seeking to develop high quality drug candidates for partnering with the biotechnology and pharmaceutical industry. Our strategy relies on seeking partners and collaborators to maximise the value of our programmes.